Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

ONE2MANY From n=1 to many: Scaling-up gene editing for future heart therapies

Coordinator
Klinikum Der Technischen Universität München (tum Klinikum), Germany
Runs
1 January 2027 to 31 December 2031
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101302158

What the project is doing

In the project's own words, from its summary on CORDIS.

Background: Genetic cardiomyopathies affect about 18 million patients worldwide and are a major cause of heart failure. LMNA mutations cause specifically severe forms of dilated cardiomyopathy (DCM). However, curative options remain extremely limited. Despite rapid advances in CRISPR-based technologies, there is no trial or approved therapy that corrects pathogenic variants directly in the human heart. Key barriers are the lack of heart-specific editors, challenging delivery to the myocardium, and mutation heterogeneity across affected genes, such as LMNA.Aim: Therefore, I aim to establish a scalable, safe, and efficient gene editing strategy for the myocardium that integrates AI-guided editor engineering, editing strategies, and programmable LNP delivery with human tissue readouts and in vivo testing.

Methods: (1) Engineer and benchmark a cardiomyocyte-optimized recombinase that requires less dsDNA donor by design. Further reduce donor toxicity by modulating innate immunity and developing a paradigm-changing new DNA donor architecture for recombinases. Define post-translational modifications and use them to engineer editors with higher efficiency in adult cardiomyocytes. (2) Build a modular editing portfolio around the “benchmark mutation” LMNA-R190W that includes exon rewriting and site-specific gene integration, with the goal to cover multiple known mutations at once. (3) Develop nonviral delivery with cardiomyocyte preference using lipid nanoparticles equipped with de novo binders and compare to AAV9 as an efficacy and safety benchmark. (4) Test these approaches in iPSC-derived cardiomyocytes, in 3D heart tissue, and in small-animal models of LMNA-R190W.Opportunities: ONE2MANY will generate a scalable editing and delivery framework that generalizes across cardiomyopathies.

It provides a new, integrated approach to think all separate components of gene editing together – editors, editing, and delivery – to finally unlock first-in-human cardiac editing,

Topics

Who is involved

OrganisationCityCountryRole
Klinikum Der Technischen Universität München (tum Klinikum)MuenchenGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI